Literature DB >> 8663221

Autoproteolysis or plasmin-mediated cleavage of factor Xaalpha exposes a plasminogen binding site and inhibits coagulation.

E L Pryzdial1, G E Kessler.   

Abstract

Blood coagulation factor Xa (FXa) has recently been shown to function as a plasminogen receptor in the presence of procoagulant phospholipid (phosphatidylserine; PS) and Ca2+. In the current work, the possible effect of autoproteolytic and plasmin-mediated cleavage of FXa on complex formation with plasminogen was investigated. 125I-plasminogen binding to derivatives of FXa electrotransferred to polyvinylidene difluoride revealed that the autoproteolytic conversion of FXaalpha to FXabeta was required for the expression of a plasminogen binding site. In the presence of PS and Ca2+, plasmin was shown to convert FXaalpha to a FXabeta-like species at least 3 orders of magnitude faster than the autoproteolytic mechanism. This also resulted in the exposure of a plasminogen binding site. Further processing by plasmin generated a fragment (33 kDa) due to cleavage at Gly331 in the FXa heavy chain. Production of this species enhanced apparent plasminogen binding compared with FXabeta and resulted in the loss of FXa amidolytic and clotting activity. In the absence of either PS or Ca2+, the plasmin-mediated fragmentation of FXaalpha was altered to include a FXabeta-like molecule and a species (40 kDa) with intact beta-heavy chain disulfide linked to a COOH-terminal fragment of the light chain starting at Tyr44. Neither of these products was observed to interact with plasminogen. The 40-kDa species had amidolytic activity comparable with FXaalpha but inhibited clotting activity. Cumulatively the data provide the first evidence for a functional difference between the FXa subforms and suggest a mechanism where autoproteolysis and plasmin-mediated cleavage modulate the function of FXaalpha from a procoagulant enzyme to a profibrinolytic plasminogen receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663221     DOI: 10.1074/jbc.271.28.16614

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Thrombolysis by chemically modified coagulation factor Xa.

Authors:  E L G Pryzdial; S C Meixner; K Talbot; L J Eltringham-Smith; J R Baylis; F M H Lee; C J Kastrup; W P Sheffield
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

2.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Authors:  Genmin Lu; Francis R DeGuzman; Stanley J Hollenbach; Mark J Karbarz; Keith Abe; Gail Lee; Peng Luan; Athiwat Hutchaleelaha; Mayuko Inagaki; Pamela B Conley; David R Phillips; Uma Sinha
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

4.  Does plasmin have anticoagulant activity?

Authors:  Jane Hoover-Plow
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

5.  Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1.

Authors:  Gourab Bhattacharjee; Jasimuddin Ahamed; Rafal Pawlinski; Cheng Liu; Nigel Mackman; Wolfram Ruf; Thomas S Edgington
Journal:  Circ Res       Date:  2008-01-03       Impact factor: 17.367

6.  Mass Spectrometry Reveals a Multifaceted Role of Glycosaminoglycan Chains in Factor Xa Inactivation by Antithrombin.

Authors:  Burcu B Minsky; Rinat R Abzalimov; Chendi Niu; Yunlong Zhao; Zachary Kirsch; Paul L Dubin; Sergey N Savinov; Igor A Kaltashov
Journal:  Biochemistry       Date:  2018-07-25       Impact factor: 3.162

Review 7.  The inflammatory actions of coagulant and fibrinolytic proteases in disease.

Authors:  Michael Schuliga
Journal:  Mediators Inflamm       Date:  2015-03-24       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.